Neuragen(R) relieves pain caused by diabetic nerve damage
New York, Sept. 16 /PRNewswire/ -- Origin BioMed recently launched its lead product Neuragen(R) in the United States. Neuragen(R) is the first non-prescription topical homeopathic treatment for rapid relief of diabetic and post-shingles nerve pain.
Neuragen(R) is effective in relieving pain in a variety of nerve related conditions. It offers distinct advantages with few or no side effects and a high level of efficacy. Neuragen(R) works in 5 to 20 minutes and provides up to eight hours of relief.
"Until recently, over-the-counter treatment options for nerve pain have been limited," said Robert Cervelli, President and CEO, Origin BioMed. "Now that Neuragen(R) is available in the United States, nerve pain sufferers will be able to significantly improve their quality of life," he added.
In the United States, approximately 23 million children and adults or 7% to 8% of the population have diabetes. While an estimated 17.9 million have been diagnosed with diabetes, 5.7 million people are unaware that they have the disease. Diabetic nerve pain occurs when high blood sugar levels damage nerves producing symptoms in about 60% to 70% of diabetics. It affects hands and feet with symptoms of numbness, tingling and pain, which may include burning and cold sensations.
"I have seen the benefits of Neuragen(R) in providing rapid and sustained pain relief among patients," said Susan Sloane, Registered Pharmacist, CDE,CPT. "This is an exciting breakthrough in the treatment of nerve pain because it is so easy to use and results may be seen in as little as five minutes. In scientific studies Neuragen(R) performed exceptionally well, confirming pain relief in greater than 70 percent of patients in some cases. Neuragen(R) is truly an impressive product with huge benefits for so many patients with diabetes who suffer from painful diabetic nerve damage."
Neuragen is available in leading pharmacies nationwide.
About Origin BioMed Inc.
Origin BioMed, Inc. is a privately-held Canadian consumer health products company with business operations throughout the U.S. and Canada. Headquartered in Halifax, Nova Scotia, Origin BioMed Inc. manufactures health products with the highest quality active ingredients, at therapeutic levels, with evidence of scientific or clinical efficacy since 2001. Its leading drug product, Neuragen(R), helps relieve pain caused by diabetic nerve damage. For more information, please visit: www.originbiomed.com or www.neuragen.com.
Origin BioMed is continuing its North American market expansion with additional financing. In July 2008, the company received $5.1 million in follow-on financing led by Calgary-based Avrio Ventures Management Corporation and Nova Scotia Business Inc. Venture Capital in support of Origin's continued growth. This new financing is helping drive the company's market expansion, placing Neuragen(R) on American drug store shelves, and supporting the growth of its U.S.-based operations.
SOURCE Origin BioMed Inc.